Published in the Journal of Clinical Medicine, the study demonstrates that administering treatment of migraine with Remote Electrical Neuromodulation (REN) does not impact blood s ...

DexCom, Inc. (NASDAQ:DXCM) is one of the 10 best healthcare equipment stocks to buy according to hedge funds. On February 13, William Plovanic from Canaccord Genuity reduced the price target on DexCom ...

Leach succeeds Abbott EVP of Diabetes Care, Chris Scoggins, in the position. Eric Benjamin, Insulet’s EVP and COO, will serve as the vice chair for the medical device industry association’s Diabetes ...

The company has integrated its Eversense 365 implant with Sequel Med Tech’s insulin delivery system to automate the management of Type 1 diabetes.

In combining the precision of the twiist insulin delivery system with the unmatched longevity of Eversense 365, Sequel and Senseonics are enhancing diabetes management by offering more tools to manage ...

Insulet stock is up on fourth-quarter results ahead of consensus, with company leaders talking about talent, technology, and ...

Insulet’s Omnipod 5 Automated Insulin Delivery (AID) System is now available in the Middle East – including Saudi Arabia, Kuwait, Qatar, and the United Arab Emirates (UAE).

Mira’s integration with ŌURA allows its users to view sleep, readiness, and temperature trends alongside their hormone data in Mira’s app.

The Omnipod 5 Automated Insulin Delivery System is now commercially available in Saudi Arabia, Kuwait, Qatar, and the United Arab Emirates, compatible with Abbott and Dexcom continuous glucose sensors ...

Investing.com - Piper Sandler has reiterated an Overweight rating on DexCom (NASDAQ:DXCM) with a price target of $75.00, aligning with the broader analyst consensus that remains strongly bullish at ...

The Omnipod 5 Automated Insulin Delivery System is now commercially available in Saudi Arabia, Kuwait, Qatar, and the United Arab Emirates, compatible with Abbott and Dexcom continuous glucose sensors ...

In his inaugural J.P. Morgan Healthcare Conference speech, newly minted Dexcom CEO Jake Leach looked to ease concerns over last year's supply shortage of the company's leading diabetes product. Leach ...